Study: NCT06302426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INI-4001
Description: INI-4001 is a small molecule TLR7/8 agonist being developed as a standalone treatment for the induction of anti-tumour immune responses and sensitization to immune checkpoint inhibitor (ICI) therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INI-4001
Description: INI-4001 is a small molecule TLR7/8 agonist being developed as a standalone treatment for the induction of anti-tumour immune responses and sensitization to immune checkpoint inhibitor (ICI) therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INI-4001
Description: INI-4001 is a small molecule TLR7/8 agonist being developed as a standalone treatment for the induction of anti-tumour immune responses and sensitization to immune checkpoint inhibitor (ICI) therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INI-4001
Description: INI-4001 is a small molecule TLR7/8 agonist being developed as a standalone treatment for the induction of anti-tumour immune responses and sensitization to immune checkpoint inhibitor (ICI) therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INI-4001
Description: INI-4001 is a small molecule TLR7/8 agonist being developed as a standalone treatment for the induction of anti-tumour immune responses and sensitization to immune checkpoint inhibitor (ICI) therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INI-4001
Description: INI-4001 is a small molecule TLR7/8 agonist being developed as a standalone treatment for the induction of anti-tumour immune responses and sensitization to immune checkpoint inhibitor (ICI) therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: During both Phase Ia and Phase Ib, patients may meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) may transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: During both Phase Ia and Phase Ib, patients may meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) may transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: During both Phase Ia and Phase Ib, patients may meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) may transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: During both Phase Ia and Phase Ib, patients may meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) may transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: During both Phase Ia and Phase Ib, patients may meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) may transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: During both Phase Ia and Phase Ib, patients may meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) may transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.